---
document_datetime: 2026-02-18 09:21:36
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.7288742
conversion_datetime: 2026-02-21 12:32:55.664406
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Cejemly

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber      | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | Q.II.b.2.c)Additionorreplacementofasite | 16/02/2026                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000332420                     | responsibleforbatchrelease(QP certification) - Q.II.b.2.c.1 Not including batch control/testing-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            | PL          |                                                                                    |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000320251 | Thiswas an applicationfor agroupof variations. B.II.FINISHED PRODUCT-B.II.zOther variation - Accepted B.IACTIVESUBSTANCE-B.I.zOther variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 20/01/2026 |            |             |                                                                                    |
| Variation type II / EMA/VR/0000261157 | C.1.6 Change(s) to therapeutic indication(s) -C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extensionofindicationtoincludethe treatment ofunresectablestageIII non-small-cell lung cancer (NSCLC) with no sensitisingEGFRmutations,orALK,ROS1 genomic tumour aberrations in adults whose disease has not progressed following concurrentorsequentialplatinum-based chemoradiotherapyforCEJEMLY,basedon finalresultsfromstudyCS1001-301;thisis a Phase Ill, multicentre, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of sugemalimab as consolidation therapy | 16/10/2025 | 21/11/2025 | SmPC and PL | Please refer to Scientific Discussion'Cejemly-H-C- 6088-II-Var.EMA/VR/0000261157'. |

<div style=\"page-break-after: always\"></div>

|                                       | advancedorunresectablestageIIINSCLC who have not progressed after concurrent or sequential chemoradiotherapy.As a consequence,sections 4.1,4.2,4.4,4.8,5.1 and5.2oftheSmPCareupdated.The PackageLeaflet is updatedinaccordance. Version2.0oftheRMPhas alsobeen agreed.                                            |            |            |             |           |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| PSUR/EMA/PSUR/0000257890              | InviewofpublishedPRACrecommendations onsignalsCoeliacdisease andPancreatic failure associated with immune checkpoint inhibitors,thePRACconcluded thatthe productinformationofsugemalimabshould be amended accordingly.                                                                                            | 24/07/2025 | 17/09/2025 | SmPC and PL | Variation |
| Variation type IB / EMA/VR/0000272096 | B.II.FINISHED PRODUCT-B.II.zOther variation - Accepted                                                                                                                                                                                                                                                            | 05/06/2025 |            |             |           |
| Article 61(3) / EMA/N/0000261048      | -Notification acc.Article 61(3)-Accepted Updateofthepackageleaflettoaddalistof localrepresentatives.Additionally,theMAH took the opportunity to align the revision date format of the package leaflet with the latestQRDtemplateandtointroduceminor editorialamendmentsto theSlovenian and Czech package leaflet. | 03/04/2025 | 17/09/2025 | PL          |           |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000263406                  | B.II.b.5 Change to in-process tests orlimits applied during the manufacture of the finished product -B.I1.b.5.a Tightening of in- process limits - Accepted   | 01/04/2025   |            |                        |             |
|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------|
| Marketing Authorisation Transfer -H / EMA/T/0000244822 | transferofmarketing authorisationfromSFL PharmaceuticalsDeutschlandGmbHto CStonePharmaceuticalsIrelandLimited                                                 | 04/02/2025   | 10/03/2025 | SmPC, Labelling and PL |             |
| PSUR/EMA/PSUR/0000296627                               |                                                                                                                                                               |              |            |                        | Maintenance |